These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 19833861

  • 1. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
    Lauring B, Dishy V, Luo WL, Laterza O, Patterson J, Cote J, Chao A, Larson P, Gutierrez M, Wagner JA, Lai E.
    J Clin Pharmacol; 2009 Dec; 49(12):1426-35. PubMed ID: 19833861
    [Abstract] [Full Text] [Related]

  • 2. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
    Dishy V, Liu F, Ebel DL, Atiee GJ, Royalty J, Reilley S, Paolini JF, Wagner JA, Lai E.
    J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
    [Abstract] [Full Text] [Related]

  • 3. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.
    Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz JA, McCrary Sisk C, Radziszewski W, Wagner JA.
    Platelets; 2010 Apr; 21(3):191-8. PubMed ID: 20163197
    [Abstract] [Full Text] [Related]

  • 4. The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
    Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E.
    Platelets; 2011 Apr; 22(7):495-503. PubMed ID: 21526889
    [Abstract] [Full Text] [Related]

  • 5. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y.
    Am J Cardiol; 2009 Jul 01; 104(1):74-81. PubMed ID: 19576324
    [Abstract] [Full Text] [Related]

  • 6. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
    Liu F, Vessey L, Wenning L, Connolly S, Buckland M, Johnson-Levonas AO, Denker A, Wagner JA, Lai E.
    J Clin Pharmacol; 2010 Jul 01; 50(7):823-8. PubMed ID: 20197486
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.
    Lai E, Wenning LA, Crumley TM, De Lepeleire I, Liu F, de Hoon JN, Van Hecken A, Depré M, Hilliard D, Greenberg H, O'Neill G, Metters K, Gottesdiener KG, Wagner JA.
    Clin Pharmacol Ther; 2008 Jun 01; 83(6):840-7. PubMed ID: 17882161
    [Abstract] [Full Text] [Related]

  • 8. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF.
    Int J Clin Pract; 2008 Dec 01; 62(12):1959-70. PubMed ID: 19166443
    [Abstract] [Full Text] [Related]

  • 9. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM.
    Am J Cardiol; 2008 Mar 01; 101(5):625-30. PubMed ID: 18308010
    [Abstract] [Full Text] [Related]

  • 10. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
    Yiu KH, Cheung BM, Tse HF.
    Expert Opin Investig Drugs; 2010 Mar 01; 19(3):437-49. PubMed ID: 20141348
    [Abstract] [Full Text] [Related]

  • 11. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.
    Lai E, De Lepeleire I, Crumley TM, Liu F, Wenning LA, Michiels N, Vets E, O'Neill G, Wagner JA, Gottesdiener K.
    Clin Pharmacol Ther; 2007 Jun 01; 81(6):849-57. PubMed ID: 17392721
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Shah S, Ceska R, Gil-Extremera B, Paolini JF, Giezek H, Vandormael K, Mao A, McCrary Sisk C, Maccubbin D.
    Int J Clin Pract; 2010 May 01; 64(6):727-38. PubMed ID: 20518948
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
    Paolini JF, Bays HE, Ballantyne CM, Davidson M, Pasternak R, Maccubbin D, Norquist JM, Lai E, Waters MG, Kuznetsova O, Sisk CM, Mitchel YB.
    Cardiol Clin; 2008 Nov 01; 26(4):547-60. PubMed ID: 19031552
    [Abstract] [Full Text] [Related]

  • 16. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
    McKenney J, Bays H, Koren M, Ballantyne CM, Paolini JF, Mitchel Y, Betteridge A, Kuznetsova O, Sapre A, Sisk CM, Maccubbin D.
    J Clin Lipidol; 2010 Nov 01; 4(2):105-112.e1. PubMed ID: 21122637
    [Abstract] [Full Text] [Related]

  • 17. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
    Schwartz JI, Liu F, Wang YH, Pramanik B, Johnson-Levonas AO, Gutierrez MJ, Lai E, Wagner JA.
    Am J Ther; 2009 Nov 01; 16(6):487-95. PubMed ID: 19940609
    [Abstract] [Full Text] [Related]

  • 18. Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
    Schwartz JI, Stroh M, Gao B, Liu F, Rosko K, Zajic S, Meehan AJ, Ruckle J, Lai E, Wagner JA.
    Cardiovasc Ther; 2009 Nov 01; 27(4):239-45. PubMed ID: 19903187
    [Abstract] [Full Text] [Related]

  • 19. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE, Maccubbin D, Meehan AG, Kuznetsova O, Mitchel YB, Paolini JF.
    Clin Ther; 2009 Jan 01; 31(1):115-22. PubMed ID: 19243712
    [Abstract] [Full Text] [Related]

  • 20. Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects.
    Lauring B, Dishy V, De Kam PJ, Crumley T, Wenning L, Liu F, Sisk C, Wagner J, Lai E.
    Am J Ther; 2015 Jan 01; 22(5):367-76. PubMed ID: 24832384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.